|
Q3 2024
|
15 |
1,233,275 |
AXSM, NUVL, APGE, AGLE
|
13F-HR
|
11/14/2024 |
000110465924118833 |
|
Q2 2024
|
13 |
885,124 |
AXSM, NUVL, AGLE, APGE
|
13F-HR
|
8/14/2024 |
000110465924089572 |
|
Q1 2024
|
15 |
917,385 |
AXSM, NUVL, APGE, DNTH
|
13F-HR
|
5/15/2024 |
000110465924061870 |
|
Q4 2023
|
16 |
946,456 |
AXSM, IMGN, NUVL, APGE
|
13F-HR
|
2/14/2024 |
000110465924023531 |
|
Q3 2023
|
20 |
831,172 |
AXSM, NUVL, IMGN, APGE
|
13F-HR
|
11/14/2023 |
000110465923118043 |
|
Q2 2023
|
17 |
709,301 |
AXSM, NUVL, IMGN, ELVN
|
13F-HR
|
8/14/2023 |
000110465923091264 |
|
Q1 2023
|
16 |
581,468 |
AXSM, NUVL, I9SA.HA, 49BA.SG
|
13F-HR
|
5/15/2023 |
000110465923060312 |
|
Q4 2022
|
16 |
630,363 |
AXSM, NUVL, I9SA.HA, 49BA.SG
|
13F-HR
|
2/14/2023 |
000110465923021407 |
|
Q3 2022
|
27 |
568,894 |
AXSM, COGT, NUVL, BCRX
|
13F-HR
|
11/9/2022 |
000110465922116268 |
|
Q2 2022
|
27 |
436,929 |
BIOHAVEN PHARMACTL HLDG CO, AXSM, BCRX, GLOBAL BLOOD THERAPEUTICS IN
|
13F-HR
|
8/15/2022 |
000110465922091338 |
|
Q1 2022
|
22 |
422,935 |
INSM, GLOBAL BLOOD THERAPEUTICS IN, ARGX, AXSM
|
13F-HR
|
5/16/2022 |
000180252822000004 |
|
Q4 2021
|
20 |
303,335 |
ZGNX, INSM, ENTA, ARGX
|
13F-HR
|
2/14/2022 |
000180252822000002 |
|
Q3 2021
|
20 |
274,991 |
INSM, ZGNX, NUVL, ALLK
|
13F-HR
|
11/15/2021 |
000180252821000008 |
|
Q2 2021
|
19 |
243,235 |
INSM, ZGNX, AXSM, ARGX
|
13F-HR
|
8/13/2021 |
000180252821000007 |
|
Q1 2021
|
21 |
237,245 |
INSM, ZGNX, IOVA, ALLK
|
13F-HR
|
5/14/2021 |
000180252821000005 |
|
Q4 2020
|
18 |
279,600 |
INSM, FOLD, IOVA, ACAD
|
13F-HR
|
2/12/2021 |
000180252821000002 |
|
Q3 2020
|
17 |
236,102 |
INSM, ACAD, TRIL, FOLD
|
13F-HR
|
11/12/2020 |
000180252820000011 |
|
Q2 2020
|
14 |
224,208 |
ACAD, INSM, ZGNX, FOLD
|
13F-HR
|
8/4/2020 |
000180252820000008 |
|
Q1 2020
|
14 |
164,882 |
ACAD, ZGNX, INSM, IOVA
|
13F-HR
|
5/8/2020 |
000180252820000006 |
|
Q4 2019
|
15 |
164,989 |
ZGNX, INSM, ACAD, AMRN
|
13F-HR
|
2/12/2020 |
000180252820000004 |